This test is most useful if any of these apply to you.
If your alkaline phosphatase stays raised without an explanation, and other findings suggest the liver is the source, this antibody can help identify primary biliary cholangitis (PBC). In PBC, the immune system damages the small bile ducts inside the liver. The disease can develop for years before symptoms appear.
AMA-M2 is an established diagnostic marker. Its meaning depends on your liver tests and the reason it was ordered, because a positive result can also occur without PBC. The amount of antibody isn't a reliable measure of how much liver damage you have.
Mitochondria are the small compartments inside your cells that help turn food into usable energy. M2 antibodies bind to proteins in several enzyme groups involved in this process. The main target is called PDC-E2, part of the machinery that helps your cells use fuel derived from carbohydrates. These proteins are present in healthy cells too; the unusual finding is the immune response against them.
M2 antibodies can belong to different antibody classes, including IgG, IgA, and IgM. One proposed trigger involves bacterial proteins that resemble the body's own mitochondrial proteins. Laboratory studies using human blood samples have found cross-reactivity between these targets. That supports a possible mechanism, but it doesn't establish that a urinary infection causes PBC.
This blood test uses an enzyme immunoassay (EIA). The assay detects antibodies that bind to M2 target proteins and reports the result in units (U). The research discussed here generally used serum obtained from blood samples. Different kits use different combinations of target proteins and may detect different antibody classes, so their numerical results aren't interchangeable.
Some assays use a laboratory-built protein called MIT3 that combines parts of three M2 targets. In one study, an IgG MIT3 assay detected antibodies in about 44% of people with PBC whose conventional microscope-based AMA test was negative. That finding shows why methods can disagree; it doesn't establish the performance of every EIA kit.
PBC mostly affects women, though men develop it too. Over time, bile duct damage can lead to liver scarring and cirrhosis. A meta-analysis of M2 enzyme immunoassays found that they detected about 83 of every 100 PBC cases and were negative in about 95 of every 100 people without PBC. Those are pooled results from different assays and study populations, not a guarantee for an individual laboratory.
Diagnosis generally requires two of three findings: a persistent liver-test pattern suggesting impaired bile flow, usually involving raised alkaline phosphatase; mitochondrial or other PBC-specific antibodies; and characteristic changes on liver biopsy. Imaging helps exclude a blocked bile duct and other explanations. A compatible alkaline phosphatase pattern plus AMA-M2 often establishes PBC without a biopsy. GGT alone is less specific.
A negative M2 result doesn't exclude PBC. Some people have antibodies that a particular assay misses, and some have PBC without detectable mitochondrial antibodies. Anti-gp210 and anti-sp100 are separate antibodies that can support the diagnosis in these cases.
PBC can be present despite normal alkaline phosphatase. In a hospital study of 165 people with PBC-related antibodies and normal alkaline phosphatase who underwent liver biopsy, about 53% had changes consistent with PBC. The group included people with AMA or AMA-M2, PBC-specific nuclear antibodies, or both. It wasn't a study of healthy people with an isolated positive M2 EIA.
Normal alkaline phosphatase also doesn't mean every liver test is normal. Other findings, including higher GGT or IgM, can raise suspicion. IgM is a class of antibody that often increases in PBC. Higher IgM helped identify biopsy-confirmed disease in the hospital study, but it couldn't establish the diagnosis by itself.
Having several PBC-related antibodies can add diagnostic evidence. In another study of people already selected for liver biopsy, about 94% of those positive for both AMA or AMA-M2 and anti-gp210 or anti-sp100 had PBC. This was the proportion diagnosed in that selected group, not the accuracy of a screening strategy for everyone with normal liver tests.
M2 antibodies can be found in people without known liver disease. A Shanghai population study using an enzyme immunoassay found positivity in about 0.94% of women and 0.40% of men. Rates differ across populations and assays, and being antibody-positive isn't the same as having PBC.
Follow-up studies have reported different rates of later PBC diagnosis. The first study below specifically enrolled people with AMA-M2 detected by enzyme or chemiluminescence immunoassays. The others included broader AMA testing or a mixture of AMA and M2 methods. They provide context for a positive result, but their findings don't translate into a risk estimate from your EIA number.
| Who Was Studied | Follow-up | What They Found |
|---|---|---|
| 2,076 Chinese adults with AMA-M2 positivity and no PBC at enrollment, identified through health checkups | Median follow-up of 6.6 years | About 6 in 1,000 developed PBC; baseline ALP, GGT, and IgM contributed to risk prediction. |
| 139 people with incidental AMA or AMA-M2 positivity and no PBC at baseline | Median follow-up of 4.6 years | The estimated five-year incidence was about 4%; higher IgM and lower ALT were associated with later diagnosis. |
| 59 Austrian participants without PBC at baseline who remained at risk and completed follow-up | About six years | Six developed PBC, or about 10% of this follow-up group. |
A French study using broader AMA testing estimated that about one in six people with normal alkaline phosphatase and no cirrhosis developed PBC within five years. These studies differed in referral patterns, baseline findings, antibody methods, and follow-up. Most participants weren't diagnosed with PBC during observation, but these results don't establish lifetime risk.
The biopsy studies and follow-up studies answer different questions. The biopsy studies examined selected people already being investigated for possible liver disease. The follow-up studies asked how often people without an established diagnosis developed one later. Your other laboratory findings help determine which setting is closer to yours.
M2 antibodies also occur in some people with myositis. Myositis is an inflammatory muscle disease that can cause weakness. Studies of antibody-positive myositis describe chronic muscle disease, sometimes involving breathing muscles, with muscle-fiber injury on biopsy.
In a Beijing cohort of 987 people hospitalized with myositis, heart involvement occurred during the disease course in 60% of the 55 antibody-positive participants, compared with about 13% of those without the antibody. After adjustment for other factors, positivity remained associated with roughly three times the rate of heart involvement. The study used several methods, including chemiluminescence, immunofluorescence, and a chip-based assay, rather than this specific EIA.
A Japanese survey of AMA-positive myositis also reported frequent heart and breathing complications. Its estimate of 380 cases referred to the number nationwide, not the number of individually evaluated participants. Among the reported cases, about 53% had heart complications and 33% had restricted ventilation. This survey concerned broader AMA-positive myositis.
These findings apply to people with myositis. They don't establish a similar heart risk in an otherwise well person with an incidental positive result. Survival wasn't significantly different between antibody-positive and antibody-negative groups in the Beijing cohort, but the study couldn't show that monitoring or a particular treatment explained that finding.
PBC and mitochondrial antibodies both cluster in families. A study using a serum enzyme immunoassay against the main M2 target found antibodies in about 13% of first-degree relatives, compared with about 1% of matched controls. That relative group included people already diagnosed with PBC; after excluding them, about 10% remained antibody-positive. Positivity was more common among female relatives.
Family history can make testing more useful, especially when considered with alkaline phosphatase. These antibody frequencies don't predict whether an individual relative will develop PBC, and the study didn't prove that antibody screening by itself improves long-term outcomes.
In a Chinese study of 530 people with PBC, serum IgG M2 measured by an enzyme immunoassay didn't reliably distinguish disease severity or treatment response. Among 203 participants followed for a median of about four years, transplant-free survival wasn't significantly different between the groups with higher and lower antibody levels.
Earlier research assays found large differences in antibody levels between people, while levels were relatively stable within individuals. A rising or falling number therefore has no established role as a treatment target. Liver chemistry, liver stiffness measurements, and the clinical picture provide more useful information about disease activity and scarring.
Repeated M2 measurements usually add little once the result and diagnosis are clear. Follow-up focuses on whether liver abnormalities emerge and, in established PBC, whether the disease responds to treatment. Antibody persistence or disappearance alone doesn't establish progression, recovery, or treatment success.
Mitochondrial M2 Antibody is best interpreted alongside these tests.